Pharmaceutical Spray Drying Market By Product Type (Equipment {Spray Dryers, Fluidized Spray Dryers, Closed Loop Spray Dryers}, Services {Contract Spray Drying, Formulation Development, Scale-up & Commercial Production}), By Application (Respiratory Drugs, Oral Solid Dosage Forms, Injectables, Dry Powder Inhalers (DPIs), Controlled Release Formulations, Sustained Release Formulations), By Drug Type (Small Molecules, Biologics), By End-user (Pharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs), Research and Academic Institutes, Government and Regulatory Agencies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Industry Outlook

The Pharmaceutical Spray Drying market accounted for USD 4.52 Billion in 2024 and is expected to reach USD 2.06 Billion by 2035, growing at a CAGR of around 7.53% between 2025 and 2035. The pharmaceutical spray drying market relies on spray drying technology to transform pharmaceutical liquids into dry powders through its process. Drug lords use this method to boost pharmaceutical stability and drug bioavailability and solubility, and this technology finds extensive application during drug development. Proof of benefit becomes most apparent when using poorly water-soluble drugs combined with inhalable medicines and controlled-release formulations. During the process, atomized liquid solutions become droplets, then hot air dries them before collecting the final product powder. Market expansion happens due to growing needs in advanced drug formulation technology as well as technical improvements in drying processes and the increasing use of biological drugs with their delivery systems. Due to its advantages for oncology, respiratory medication administration, and pediatric drug research, the pharmaceutical industry invests in spray drying to increase therapeutic efficacy. Regulatory approvals for spray-dried formulations continue to rise, which further supports the market's expansion.

Report Scope:

Market Dynamics

Spray drying enhances bioavailability, driving its adoption in drug development.

The pharmaceutical spray drying market operates because it improves drug absorption for poorly water-soluble drugs, which makes it indispensable for contemporary drug development. Remarkable demand exists for spray drying to process low-solubility active pharmaceutical ingredients (APIs) because it enhances drug uptake and treatment outcomes. Spray drying achieves better adoption in biologic substance formation because of improved systems, which include nano spray drying and closed-loop processes. The market expands because spray drying enables manufacturers to produce DPIs and ODTs with precise particle size control, thus increasing demand for these products.

Pharmaceutical firms increasingly delegate spray drying operations to contract development and manufacturing organizations (CDMOs) to get better workflow efficiency, together with cost reduction. The U.S. Food and Drug Administration reports that excessive water solubility affects more than 40% of new chemical entities, thus demonstrating that spray drying plays a critical role in drug formulation.

Increased demand for biologics, including vaccines and peptides, boosts spray drying applications.

The pharmaceutical spray drying market shows continuous expansion because manufacturers need advanced formulation methods to stabilize biologic drugs such as vaccines and peptides. Spray drying serves as the primary biologic drug production method because it extends stability while improving uptake ability and allowing precise therapeutic delivery. Markets expand due to escalating interest in spray-dried vaccine manufacturing, mainly for inhalable item delivery, which requires no needles. The stability-enhancing capabilities of spray drying regenerate peptide drugs as these compounds naturally degrade when exposed to certain conditions.

Market investments in spray drying technology surged because of two simultaneous trends: the expanding number of chronic diseases and the assembly of biopharmaceutical research programs. The World Health Organization (WHO) reports that more than half of the drugs currently in development belong to the biologic category, which demonstrates the essential need for sophisticated formulation methods, including spray drying.

Spray drying equipment and facility setup require significant investment.

The pharmaceutical spray drying market experiences substantial restriction because the installation of equipment and facilities demands significant capital investment. Applications of spray drying technology for pharmaceuticals require sophisticated equipment featuring advanced control features for temperature regulation and solvent recovery, and continuous operation systems to achieve stability together with regulatory adherence. Large pharmaceutical companies, together with CDMOs, face escalating financial challenges because of establishing manufacturing facilities operating within GMP standards.

The total manufacturing expenditure increases because of operational costs, which include maintenance requirements, energy usage, and workforce-related expenses. Such expensive costs create obstacles for small and medium-sized pharmaceutical corporations, who face restricted market growth opportunities. Spray drying exists mainly because large pharmaceutical companies maintain appropriate resources for adopting this technology.

Enhancing stability and shelf life of probiotics for gut health applications.

The pharmaceutical spray drying market offers substantial avenues to develop stable probiotics for gut health applications through improved shelf life. The viability of probiotics diminishes when storage occurs in conditions where moisture, temperature, and oxygen interact since they are easily sensitive to these elements. Through the spray drying process, beneficial bacteria can become stable, dry powder forms, which extend their lifespan and enhance their functionality.

The technique provides controlled-release formulations, which help maintain probiotic therapeutic benefits from intact delivery to the intestines. Pharmaceutical and nutraceutical companies invest in advanced spray drying solutions because customers increasingly seek probiotic supplements along with enhanced understanding of gut health benefits. The spray drying technique enables commercial manufacturers to produce probiotics at scale while maintaining high product quality; thus, it has become the preferred manufacturing method for industry-level probiotic products.

Enabling precise drug delivery in regenerative medicine and genetic treatments.

The pharmaceutical spray drying market creates substantial commercial prospects because its technology enables precise delivery methods for regenerative medicine, together with genetic treatments. The stable and targeted delivery of drug carriers, including nanoparticles and microparticles, becomes possible through spray drying technology since these drug carriers serve to deliver sensitive biologics, including gene therapies, stem cells, and growth factors.

This technology manages drug release durations while improving drug absorption levels to deliver better treatment effects for genetic disorder and degenerative disease patients. Spray-dried formulation technology helps stabilize delicate biomolecules by shielding them from deterioration and thus extends their usable period and performance capabilities. Pharmaceutical companies use spray drying techniques to create future drug delivery approaches because of increased funding for regenerative medicine and personalized therapy advancements. Its position in precision medicine becomes stronger because of its customizable particle specifications.

Industry Experts Opinion

"Spray drying has become a cornerstone in pharmaceutical manufacturing, particularly for enhancing the solubility and bioavailability of poorly water-soluble drugs. This technology allows for precise particle size control, leading to more effective drug delivery systems."

• Dr. Mark Peterson, Senior Pharmaceutical Scientist at the Institute of Drug Formulation

Segment Analysis

Based on the Application, the Pharmaceutical Spray Drying Market has been classified into Equipment and Services. Among all segments of the pharmaceutical spray drying market, the equipment category holds its position as the biggest section because pharmaceutical companies continue to adopt spray dryers to enhance drug stability along with increased solubility as well as bioavailability. Production of suitable drug particles for inhalable drugs while maintaining both oral solid dosage form control and biologic stability is possible through spray dryers, fluidized spray dryers, and closed-loop spray dryers in pharmaceutical manufacturing operations.

The high demand for closed-loop spray dryers exists because these devices tolerate solvent materials effectively and serve as suitable equipment for processing heat-sensitive volatile substances. Pharmaceutical companies, together with contract development and manufacturing organizations, dedicate increasingly more resources to high-performance spray drying technology, which continues to be the fundamental technology for advancing drug formulations. The market adoption of spray drying systems continues to escalate because regulatory agencies stress precision drug delivery while requiring GMP compliance.

Based on the product type, the Pharmaceutical Spray Drying Market has been classified into Respiratory Drugs, Oral Solid Dosage Forms, Injectables, Dry Powder Inhalers (DPIs), Controlled Release Formulations, and Sustained Release Formulations. The Oral solid dosage forms dominate the pharmaceutical spray drying market sector because they are commonly used for creating tablets and capsules. Spray drying enables pharmaceutical companies to choose this technique because it improves both drug solubility and bioavailability for poorly water-soluble products. Spray drying technology enables pharmaceutical manufacturers to create controlled-release formulations that combine with sustained-release elements for improved patient medicine adherence and therapeutic outcomes.

The rising market need for advanced oral medication requires pharmaceutical manufacturers to develop improved spray drying methods that enhance drug stability and absorption capabilities. The dominance of this segment increases further because pharmaceutical companies choose patient-friendly dosage forms such as orally disintegrating tablets (ODTs). The combination of regulatory backing for better drugs and affordable large-scale manufacturing programs generates steady market growth in this product category.

Regional Analysis

The pharmaceutical spray drying market is primarily dominated by North America because it houses pharmaceutical companies strongly coupled with advanced drug production facilities and significant research & development expenses. The United States stands at the forefront of the regional market because pharmaceutical firms continuously increase their demand for spray-dried formulations to develop biologics as well as inhalable drugs and controlled-release medications.

CDMOs and major pharmaceutical firms together drive market expansion because pharmaceutical companies demand effective spray drying methods for pharmaceutical solubility enhancement. The U.S. FDA regulates pharmaceutical manufacture through good manufacturing practice (GMP)-compliant spray drying facilities based on requirements. Demand for dry powder inhalers (DPIs) is rising owing to increasing respiratory diseases, which enhances the market demand.

Rapid expansion across the Asia-Pacific pharmaceutical spray drying market occurs due to continuous growth in pharmaceutical production, a growing generic drug industry, and increasing demand for contracted manufacturing services. The three nations, China, India, and Japan, participate as major players in this market due to governmental backing for pharmaceutical development initiatives.

The pharmaceutical spray drying market expands due to increasing industrial use of spray drying for biologics and nutraceutical products. Regional pharmaceutical companies increasingly regard the area as appealing because CDMOs are reducing their production expenses and expanding their spray drying infrastructure. The combination of regulatory advancements together with an increasing incidence of chronic diseases encourages regional market demand for spray-dried drug formulations.   

Competitive Landscape

The pharmaceutical spray drying market exhibits intense competition because of developing technologies combined with rising biologics use and expanding need for solubility-enhanced pharmaceuticals. The leading companies in the market, including GEA Group, Büchi Labortechnik, and SPX FLOW, concentrate on manufacturing upgraded spray drying equipment that shows greater efficiency while allowing for better scalability. The pharmaceutical market sees contract development and manufacturing organizations (CDMOs) Catalent and Lonza create new spray drying facilities to assist pharmaceutical processors who choose contract manufacturing. The companies Hovione and Evonik Industries spend funds on developing advanced spray drying methods to handle complex pharmaceutical molecules.

The intense market competition revolves around equipment innovation and contract manufacturing as well as regulatory compliance because companies find success in cost-effective solutions and GMP-certified facilities and precision technology. The strategic market movement includes rising mergers and acquisitions and partnerships that help companies develop broader service offerings while expanding internationally.

Pharmaceutical Spray Drying Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2023, Experic, a CDMO and clinical trial supply services provider for the biopharmaceutical industry, expanded its capabilities by incorporating spray drying technology to enhance biopharmaceutical formulation and development.
• In February 2023, EUROAPI installed a new spray dryer at its R&D center in Haverhill, UK, to strengthen its pharmaceutical process development and scale-up capabilities for its CDMO clients.

Frequently Asked Questions (FAQs)